FGFR Inhibition and Chemoresistance: Insights from BGJ 398 and PD 173074

Study Background and Research Question

Chemoresistance remains a central challenge in the treatment of solid tumors, particularly those treated with microtubule-targeting agents such as paclitaxel and doxorubicin. A key mechanism underlying multidrug resistance (MDR) is the overexpression of ATP-binding cassette (ABC) transporters, notably P-glycoprotein (ABCB1), which actively expel chemotherapeutic agents from cancer cells. The fibroblast growth factor receptor (FGFR) signaling pathway has emerged as a promising target in oncology, as aberrant FGFR activity is implicated in tumor proliferation, survival, and resistance to therapy. However, whether FGFR inhibition can modulate MDR, and if so, via which mechanisms, has been an open research question.

Key Innovation from the Reference Study

The recent study by Boichuk et al. (Biomedicines 2022, 10, 601) delivers a notable advance by demonstrating that infigratinib (BGJ 398), a potent pan-FGFR inhibitor, can sensitize a range of ABCB1-overexpressing cancer cell lines to chemotherapeutic agents. The study uniquely identifies ABCB1 as a direct molecular target for BGJ 398, showing that the compound impairs ABCB1-mediated drug efflux. Importantly, the study contrasts BGJ 398 with PD 173074, another well-characterized FGFR1/VEGFR2 inhibitor, finding that PD 173074 does not share this chemosensitizing property. This direct comparative approach clarifies the mechanistic and functional diversity among FGFR tyrosine kinase inhibitors in the context of MDR.

Methods and Experimental Design Insights

The research employed a combination of biochemical, molecular, and cell-based assays. Key elements of the experimental design included:

• Use of multiple cancer cell lines with established multidrug-resistant phenotypes, including triple-negative breast cancer (TNBC) and gastrointestinal stromal tumor (GIST) models, characterized by ABCB1 overexpression.
• Drug treatment regimens evaluating single agents (BGJ 398, PD 173074, paclitaxel, or doxorubicin) and combinations (FGFR inhibitor plus chemotherapeutic agent).
• Assessment of cell viability, proliferation, and apoptosis by standard metrics (PARP and caspase-3 cleavage, Annexin V staining).
• Evaluation of drug efflux using fluorescently labeled chemotherapeutics (Flutax-2 for paclitaxel, intrinsic fluorescence for doxorubicin, and Calcein AM as an ABCB1 substrate).
• Western blot analysis to monitor FGFR pathway activity (phosphorylated FGFR, FRS-2, STAT1/3, S6) and ABC transporter expression.

The study design allowed for direct comparison of FGFR inhibition on both signaling and MDR phenotypes, and for discrimination between effects attributable to FGFR signaling versus ABCB1 modulation.

Core Findings and Why They Matter

The reference study established several critical findings:

• BGJ 398 Restores Chemosensitivity: Infigratinib re-sensitized MDR cancer cells to paclitaxel and doxorubicin, as evidenced by increased apoptosis markers and reduced proliferation when used in combination with chemotherapeutics. This effect was absent when BGJ 398 was used as a single agent.
• ABCB1-Dependent Mechanism: BGJ 398 impaired the efflux of chemotherapeutic agents and Calcein AM from resistant cells, implicating direct inhibition of ABCB1 function. Notably, this did not affect the expression levels of ABC transporters, suggesting a functional inhibition rather than downregulation.
• FGFR Pathway Inhibition Validated: Both BGJ 398 and PD 173074 inhibited FGFR signaling, as shown by reductions in phosphorylated FGFR and downstream effectors.
• PD 173074 Lacks Chemosensitization via MDR Modulation: PD 173074 did not retain chemotherapeutic agents within ABCB1-overexpressing cells and failed to sensitize resistant cells to paclitaxel or doxorubicin, despite its potent inhibition of FGFR1 and VEGFR2. This underscores mechanistic specificity among FGFR inhibitors (reference).

These findings clarify that not all selective FGFR1 inhibitors or FGFR tyrosine kinase inhibitors possess the ability to reverse MDR via ABCB1 inhibition, emphasizing the need for functional validation when selecting research tools for studies of drug resistance.

Comparison with Existing Internal Articles

Several internal resources elaborate on the utility of PD 173074 (SKU A8253) as a selective, nanomolar-potency inhibitor of FGFR1 and VEGFR2:

• The article "Scenario-Driven Solutions for FGFR..." provides practical strategies for optimizing FGFR and VEGFR pathway inhibition workflows using PD 173074, with a focus on reproducibility in cell viability and multidrug resistance studies. However, as supported by the reference study, PD 173074 does not functionally block ABCB1-mediated drug efflux, limiting its utility for investigating MDR reversal mechanisms.
• "Precision FGFR1/VEGFR2 Inhibition for Cancer Research" details experimental guidance for using PD 173074 in angiogenesis inhibition and kinase signaling studies. While effective for dissecting FGFR and VEGFR pathways, these workflows should not be assumed to address ABC transporter-mediated resistance without additional functional evidence.

The present study thus delineates a clear boundary: PD 173074 is highly suitable for mechanistic studies of FGFR/VEGFR signaling and angiogenesis inhibition, but direct modulation of ABCB1-driven MDR requires alternative compounds such as BGJ 398.

Limitations and Transferability

While the reference work rigorously demonstrates the ability of BGJ 398 to inhibit ABCB1-mediated drug efflux and restore chemosensitivity in vitro, several caveats must be considered:

• All data were generated in cell culture models; in vivo confirmation of ABCB1 targeting and MDR reversal by BGJ 398 is needed, especially considering the complexity of drug distribution and transporter expression in animal models and human tumors.
• The inability of PD 173074 to reverse MDR suggests that not all FGFR inhibitors share this property, likely due to differences in off-target or transporter interactions. Results should not be extrapolated to other kinase inhibitors without direct evidence.
• The study does not address the impact of long-term FGFR inhibition or potential compensatory mechanisms in cancer cells that might influence MDR in vivo.

For researchers, these limitations highlight the necessity for careful selection of chemical probes and the importance of functional validation in relevant models before drawing conclusions regarding MDR modulation.

Protocol Parameters

• BGJ 398 (infigratinib) treatment: Applied at concentrations sufficient for robust FGFR inhibition (typically low nanomolar to submicromolar), followed by combination with paclitaxel or doxorubicin to assess chemosensitivity in ABCB1-overexpressing cell lines (reference study).
• PD 173074 (SKU A8253): For FGFR1/VEGFR2 pathway inhibition and angiogenesis assays, typical experimental concentrations range from 10-100 nM in cell culture and 1-2 mg/kg/day (i.p.) for animal models, as described in the product information.
• Drug efflux assays: Use fluorescent substrates such as Flutax-2, doxorubicin, and Calcein AM to monitor retention in MDR cell models when testing novel MDR modulators.
• Apoptosis quantification: Assess by Annexin V staining and immunoblot detection of cleaved PARP and caspase-3.

Research Support Resources

Researchers interested in dissecting FGFR or VEGFR signaling pathways, angiogenesis inhibition, or kinase-signaling mechanisms may employ PD 173074 (SKU A8253), a highly selective FGFR1/VEGFR2 inhibitor available from APExBIO (see internal article for workflow examples). While PD 173074 does not reverse ABCB1-mediated multidrug resistance according to the study above, it provides robust and selective pathway inhibition for a wide range of cell-based and in vivo models where FGFR/VEGFR signaling is under investigation. Always validate functional outcomes relevant to your specific research question.